Covista (CVSA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Oct, 2026Executive summary
FY26 revenue rose 9.3% to $1.954B and adjusted EPS rose 23.7% to $8.25; both exceeded the high end of guidance. Three-year total shareholder return was 263%.
Purpose at Scale targets 7%–10% revenue CAGR, 10%–14% adjusted EPS CAGR and enrollment above 120,000 through FY29; targets are not forecasts.
FY26 ended with 99,472 students, $471M operating cash flow from continuing operations, $238M in share repurchases and $406M cash; net leverage was 0.5x adjusted EBITDA.
Voting matters and shareholder proposals
At the Nov. 11, 2026 virtual annual meeting, shareholders will vote on 11 director nominees, PwC ratification for FY27, advisory approval of FY26 NEO compensation and the 2026 Equity Incentive Plan; the Board recommends FOR each.
If approved, the 2026 Plan takes effect Nov. 11, 2026, reserves 2.1M shares and replaces the prior plan for new awards; the Board estimates the reserve could support grants for ~4 years.
Proposal 4 adds a one-year minimum vesting rule, bars repricing without shareholder approval and caps most non-employee director compensation at $750,000 per FY.
Board of directors and corporate governance
Eleven nominees stand for election through the 2027 annual meeting; 90% of current directors and nominees are independent, with an average tenure of 5.2 years and average age of 60.6.
Emily Chiu and Leslie Storms joined in August 2026; Lisa Wardell will retire from the Board, reducing its size to 11. The retirement-age policy was waived for Donna Hrinak’s renomination at age 75.
CEO Stephen Beard also serves as Board Chair; Michael Malafronte is Lead Independent Director and presided over FY26 independent-director executive sessions.
Shareholder outreach reached holders of more than 70% of shares owned; governance updates included a 10b5-1 trading-plan requirement for director and executive stock sales, subject to limited hardship exceptions.
Latest events from Covista
- Board backs all four voting matters at the November 11, 2026 virtual meeting.CVSA
Proxy filing - Sustained growth, campus expansion, and strategic partnerships drive a leading healthcare education platform.CVSA
2026 Jefferies Healthcare Services and Technology Conference - Double-digit EPS growth, record enrollments, and strong FY27 outlook delivered.CVSA
Q4 2026 - Record enrollment and revenue growth, raised guidance, and strong capital allocation.CVSA
Q3 2026 - AI-driven growth and operational excellence support double-digit earnings and enrollment targets.CVSA
Investor Day 2026 - Raised EPS guidance, strong enrollment, and $750M buyback drive robust financial results.CVSA
Q2 2026 - Enrollment and revenue growth drive strong earnings and positive 2026 outlook.CVSA
Q1 2026 - Double-digit enrollment and revenue growth drive record results and strong FY25 outlook.CVSA
Q4 2024 - Record enrollment and margin gains highlight strong growth in healthcare education.CVSA
Baird 2024 Global Consumer, Technology & Services Conference